NX-5948, Nurix Therapeutics’ treatment for relapsed or refractory chronic lymphocytic leukemia, and Ga68-PentixaFor, Pentixapharm’s radiodiagnostic for primary aldosteronism, are the latest investigational products to secure a place on PRIME, the European Medicines Agency’s priority medicines scheme for drugs addressing unmet medical needs.
Key Takeaways
- NX-5948 and Ga68-PentixaFor are the latest entries on the PRIME scheme, bringing to 141 the total number of products to secure a place on the scheme.
NX-5948 was among nine applications for a place on PRIME that the EMA’s human medicines committee, the CHMP, reviewed at...